What is PFE's current stock price?

As of now, PFE is trading at $24.69, with a daily change of +0.69%.

What are the risks associated with PFE stock?

PFE Key risk is its Low Risk Level, .

What is PFE next earnings date?

PFE next earnings report is scheduled for Nov 4, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

PFE Stock Analysis & IQ Rating | Pfizer

PFE

Pfizer

$24.69

+$0.17 | +0.69%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 29.22

MKT CAP

$ 140.35B

52W Low

$ 20.92

VOL

$ 31.51M

P/E Ratio

13.1

AVG VOL

$ 57.72M

RSI

46.98

TREND

Sideways

PFE Stock IQ

Login to see Pfizer (PFE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

PFE Target Price

Login to display

Strengths

PFE Rewards

Earnings are forecast to grow

PFE Rewards

Trading below its fair value

PFE Rewards

Investors confidence is positive

PFE Rewards

Upgraded on attractively valued

Chart

$24.09 (+2.49%)

$24.3 (+1.60%)

$23.49 (+5.11%)

$27.76 (-11.06%)

1year

6month

3month

1month

PFE Risk Level

PFE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

LOW

HIGH

PFE Analysts Opinion

PFE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

PFE Analysts Opinion

PFE Analysts opinion is positive and also has improved from the past 3 months

PFE Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

90%

84%

PFE Street Opinion

PFE Street view is extremely bullish and have positive views on the near-term outlook

PFE Performance Sentiment

Sentiments overview associated with PFE events and the stock performance.

84%

11%

Positive

Negative

91 out of 108
events present

12 out of 108
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$24.51

Resistance
Price

$23.60

Current Price Range

$27.37

Show methods +

PFE Earnings

The TTM reflects 12-month period, providing review of PFE financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

63,833

63,627

59,553

+3.53%

Cost of Revenue

17,796

17,851

24,954

-15.55%

Gross Profit

46,037

45,776

34,599

+15.35%

Operating Exp

29,374

30,838

30,183

-1.35%

Operating Inc

16,663

14,938

4,416

+94.25%

Net Interest Inc

-2,246

-2,546

-585

-

Interest Exp

2,831

3,091

2,209

+13.21%

Interest Inc

585

545

1,624

-39.98%

Other Inc Exp

-3,884

-4,369

-2,774

-

EPS Growth

1.89

1.42

0.38

+123.02%

PFE Financial Health

The company financial health has moderately improved over the past year

Financial Score

4.06

Next Earnings Date: Nov 4, 2025

Linked to PFE

IQ

Close Price

Change

NVS

4.26

131.80

+0.27%

SNY

3.93

49.73

-1.76%

MRK

4.11

86.32

+1.80%

AZN

4.15

83.87

-0.97%

ABBV

4.05

232.06

+1.04%

PFE Latest Analysis +

Pfizers Q3 Non-Oncology Performance: Heres What to Expect. Pfizers Q3 results are set to reveal mixed trends across non-oncology drugs with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Today

$24.69 | +0.69%

Potential

Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study . (RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma United States Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide) in combination with leuprolide and as monotherapy in men with non-metastatic hormone-sensitive prostate cancer (nm

Today

$24.69 | +0.69%

Potential

ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million. Key PointsSold entire holding of 109630 shares. estimated trade value of approximately $2.66 million based on the quarterly average price

Thu Oct 16, 2025

$24.23 | -0.70%

Activity

A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years. Key PointsPfizers recent issues include poor financial results looming patent cliffs and the potential impact of tariffs.

Thu Oct 16, 2025

$24.23 | -0.70%

Activity

Earnings

Potential

Pfizer: Dont Forget About Value During AI Frenzy.

Thu Oct 16, 2025

$24.23 | -0.70%

Potential

CEOs of Wells Fargo and Pfizer caution the United States could lose its edge to China without innovation . Speaking at CNBCs Invest in America Forum the CEOs said the United States still leads in many sectors but inconsistent policy and underinvestment is ceding ground.

Wed Oct 15, 2025

$24.39 | -0.53%

Activity

Pfizer CEO touts Chinas dramatic speed in biopharma calls for United States collaboration.

Wed Oct 15, 2025

$24.39 | -0.53%

Activity

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug. ) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.This trial tested a new treatment for patients with a type of breast cancer () that is positive for HER2 which means the cancer cells have a specific protein that helps them grow.The treatment combines a drug called Tukysa (tucatinib) which is a type of medicine that targets cancer cells with other therapies. The trial is in its third phase which means i

Tue Oct 14, 2025

$24.52 | -0.85%

Activity

Pfizer (PFE) Shares Cross 7% Yield Mark. Looking at the universe of stocks we cover at Dividend Channel in trading on Tuesday shares of Pfizer Inc (Symbol: PFE) were yielding above the 7% mark based on its quarterly dividend (annualized to $1.72) with the stock changing hands as low as $24.51 on the day. Dividends

Tue Oct 14, 2025

$24.52 | -0.85%

Activity

Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy.

Tue Oct 14, 2025

$24.52 | -0.85%

Activity

FAQ About PFE Stock Insights

What is PFE current stock price?

What are PFE stock strengths?

What risks are associated with PFE stock?

When is PFE next earnings report?

What is PFE market cap and volume?

What is PFE's current Stock IQ?

Should I buy PFE stock right now?

Is PFE a Strong Buy right now?

What does a 'Strong Buy' rating mean for PFE?

What does a 'Strong Sell' rating mean for PFE?

What factors influence PFE's Stock IQ?

Explore our PFE Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored PFE Stock Strategies
Effective Risk Management

FIND US ON

Receive our PFE Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

PFE

Pfizer

Current Price

$24.69

+$0.17 | +0.69%

52W High

$ 29.22

MKT CAP

$ 140.35B

52W Low

$ 20.92

VOL

$ 31.51M

P/E Ratio

13.1

AVG VOL

$ 57.72M

RSI

46.98

TREND

Sideways

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

PFE Rewards

Earnings are forecast to grow

PFE Rewards

Trading below its fair value

PFE Rewards

Investors confidence is positive

PFE Rewards

Upgraded on attractively valued

Linked to PFE

Symbol

IQ

Close

Change

NVS

4.26

131.80

+0.27%

SNY

3.93

49.73

-1.76%

MRK

4.11

86.32

+1.80%

AZN

4.15

83.87

-0.97%

ABBV

4.05

232.06

+1.04%

PFE Stock IQ

Login to unlock Pfizer (PFE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$24.09 (+2.49%)

$24.3 (+1.60%)

$23.49 (+5.11%)

$27.76 (-11.06%)

1year

6month

3month

1month

PFE Analysts Opinion

PFE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

PFE Analysts Opinion

PFE Analysts opinion is positive and also has improved from the past 3 months

PFE Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

90%

84%

PFE Street Opinion

PFE Street view is extremely bullish and have positive views on the near-term outlook

PFE Risk Level

PFE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

LOW

HIGH

PFE Performance Sentiment

Sentiments overview associated with PFE events and the stock performance.

84%

11%

Positive

Negative

91 out of 108
events present

12 out of 108
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$24.51

Resistance
Price

$23.60

Current Price Range

$27.37

Show methods +

PFE Earnings

The TTM data reflects the most recent 12-month period, providing overview of PFE financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

63,833

63,627

59,553

+3.53%

Cost of Revenue

17,796

17,851

24,954

-15.55%

Gross Profit

46,037

45,776

34,599

+15.35%

Operating Exp

29,374

30,838

30,183

-1.35%

Operating Inc

16,663

14,938

4,416

+94.25%

Net Interest Inc

-2,246

-2,546

-585

-

Interest Exp

2,831

3,091

2,209

+13.21%

Interest Inc

585

545

1,624

-39.98%

Other Inc Exp

-3,884

-4,369

-2,774

-

EPS Growth

1.89

1.42

0.38

+123.02%

PFE Financial Health

The company financial health has moderately improved over the past year

Financial Score

4.06

Next Earnings Date: Nov 4, 2025

PFE Latest Analysis

Pfizers Q3 Non-Oncology Performance: Heres What to Expect. Pfizers Q3 results are set to reveal mixed trends across non-oncology drugs with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Today

$24.69 | +0.69%

Potential

Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study . (RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma United States Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide) in combination with leuprolide and as monotherapy in men with non-metastatic hormone-sensitive prostate cancer (nm

Today

$24.69 | +0.69%

Potential

ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million. Key PointsSold entire holding of 109630 shares. estimated trade value of approximately $2.66 million based on the quarterly average price

Thu Oct 16, 2025

$24.23 | -0.70%

Activity

A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years. Key PointsPfizers recent issues include poor financial results looming patent cliffs and the potential impact of tariffs.

Thu Oct 16, 2025

$24.23 | -0.70%

Activity

Earnings

Potential

Pfizer: Dont Forget About Value During AI Frenzy.

Thu Oct 16, 2025

$24.23 | -0.70%

Potential

CEOs of Wells Fargo and Pfizer caution the United States could lose its edge to China without innovation . Speaking at CNBCs Invest in America Forum the CEOs said the United States still leads in many sectors but inconsistent policy and underinvestment is ceding ground.

Wed Oct 15, 2025

$24.39 | -0.53%

Activity

Pfizer CEO touts Chinas dramatic speed in biopharma calls for United States collaboration.

Wed Oct 15, 2025

$24.39 | -0.53%

Activity

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug. ) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.This trial tested a new treatment for patients with a type of breast cancer () that is positive for HER2 which means the cancer cells have a specific protein that helps them grow.The treatment combines a drug called Tukysa (tucatinib) which is a type of medicine that targets cancer cells with other therapies. The trial is in its third phase which means i

Tue Oct 14, 2025

$24.52 | -0.85%

Activity

Pfizer (PFE) Shares Cross 7% Yield Mark. Looking at the universe of stocks we cover at Dividend Channel in trading on Tuesday shares of Pfizer Inc (Symbol: PFE) were yielding above the 7% mark based on its quarterly dividend (annualized to $1.72) with the stock changing hands as low as $24.51 on the day. Dividends

Tue Oct 14, 2025

$24.52 | -0.85%

Activity

Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy.

Tue Oct 14, 2025

$24.52 | -0.85%

Activity

Discover PFE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of PFE. We're here to help you make informed investment decisions today.

FIND US ON

Receive our PFE Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

PFE Stock trends

PFE Stock performance

PFE Stock analysis

PFE investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing PFE

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing PFE

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

PFE Stock Analysis & IQ Rating | Pfizer

PFE Stock IQ

PFE Target Price

PFE Risk Level

PFE Analysts Opinion

PFE Street Consensus

PFE Performance Sentiment

Technical Price Levels

PFE Financial Health

Explore our PFE Stock insights

Receive our PFE Daily Alerts

PFE Stock IQ

PFE Street Consensus

PFE Risk Level

Technical Price Levels

Discover PFE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of PFE. We're here to help you make informed investment decisions today.

Receive our PFE Daily Alerts

PFE Runner Alarm